AVI BioPharma Announces Presentations On Exon Skipping Drug AVI-4658 For Treatment Of Duchenne Muscular Dystrophy

Main Category: Muscular Dystrophy / ALS
Article Date: 19 Jul 2010 - 3:00 PDT

email to a friend   printer friendly   opinions  

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced upcoming presentations on AVI-4658, the Company's exon skipping therapy for the treatment of Duchenne muscular dystrophy, at the XII International Congress on Neuromuscular Diseases taking place July 17-22, 2010 in Naples, Italy. The presentations will highlight results from Study 28, the recently completed Phase 1b/2 clinical trial of AVI-4658.

Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer at AVI, will present on Sunday, July 18 during poster session 5B: Muscular Dystrophies: State of the Art in Diagnosis & RNA Modulation for Duchenne Muscular Dystrophy. Dr. Shrewsbury's presentation is titled "Current Progress with the Systemic Administration Trial of AVI-4658, a Novel Phosphorodiamidate Morpholino Oligomer (PMO) Skipping Dystrophin Exon 51 in Duchenne Muscular Dystrophy (DMD)."

In addition, Dr. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England will present on Monday, July 19 during a late-breaking poster session. His presentation is titled "Systemic Administration of AVI-4658 a Phosphorodiamidate Morpholino Oligomer (PMO) Restores Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Boys in a Dose Dependent Manner."

Both presentations will be posted on the AVI BioPharma website the afternoon of Monday, July 19.

AVI-4658 is AVI's lead drug candidate being developed as a systemically administered treatment for a substantial subgroup of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin.

Source:
AVI BioPharma

• Additional
• References
• Citations